Mouse Monoclonal ALK antibody. Suitable for WB and reacts with Rat samples.
pH: 7.5
Constituents: HEPES, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride, 0.01% BSA
WB | |
---|---|
Human | Predicted |
Rat | Tested |
Hamster | Predicted |
Pig | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Hamster, Human, Pig | Dilution info - | Notes - |
Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). Following activation by ALKAL2 ligand at the cell surface, transduces an extracellular signal into an intracellular response (PubMed:30061385, PubMed:33411331, PubMed:34646012, PubMed:34819673). In contrast, ALKAL1 is not a potent physiological ligand for ALK (PubMed:34646012). Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway (PubMed:34819673). Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif (PubMed:15226403, PubMed:16878150). Induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1 (PubMed:15226403, PubMed:16878150). ALK activation may also be regulated by pleiotrophin (PTN) and midkine (MDK) (PubMed:11278720, PubMed:11809760, PubMed:12107166, PubMed:12122009). PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation (PubMed:11278720, PubMed:11809760, PubMed:12107166). MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction (PubMed:12122009). Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase (PubMed:15226403, PubMed:16878150). Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK (PubMed:15226403, PubMed:16878150).
CD246, ALK tyrosine kinase receptor, Anaplastic lymphoma kinase, ALK
Mouse Monoclonal ALK antibody. Suitable for WB and reacts with Rat samples.
pH: 7.5
Constituents: HEPES, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride, 0.01% BSA
Purified from culture supernatant.
Syntaxin 1a also known as STX1A is an essential protein in cellular mechanisms involved in neurotransmitter release. This protein weighing approximately 33 kDa plays a direct role in synaptic vesicle fusion through its function as a member of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein Receptor) complex. Syntaxin 1a is highly expressed in the brain especially in areas like the hippocampus and cerebral cortex where it facilitates rapid neurotransmission important for communication between neurons.
The involvement of Syntaxin 1a in synaptic transmission is significant. It forms a complex with other proteins such as SNAP-25 and VAMP enabling the docking and fusion of synaptic vesicles with the presynaptic membrane. This action results in the release of neurotransmitters into the synaptic cleft which then bind to receptors on the postsynaptic neuron to propagate neural signals. Syntaxin 1a ensures efficient synaptic activity and is indispensable for maintaining synaptic plasticity which is critical for learning and memory.
Syntaxin 1a is pivotal in the regulation of neurotransmitter release within the synaptic vesicle cycle pathway. This pathway includes the assembly and disassembly of the SNARE complex which are processes vital for neurotransmitter exocytosis. Syntaxin 1a engages closely with proteins like synaptotagmin acting as calcium sensors and Munc18 which helps in initiating SNARE assembly. These interactions highlight the careful orchestration of vesicle trafficking and fusion events necessary for effective synaptic communication.
Dysfunctions in Syntaxin 1a are linked to neurological conditions such as epilepsy and autism spectrum disorders. Alterations or mutations in Syntaxin 1a can lead to improper synaptic vesicle fusion and disrupted neurotransmitter release which are characteristics of these disorders. Additionally Syntaxin 1a interacts with proteins like Munc18-1 whose mutations are associated with similar synaptic transmission deficiencies further implicating the involvement of Syntaxin 1a in these pathologies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-Syntaxin 1a antibody [SP8] (ab254124) at 1/1000 dilution
All lanes: Rat cortex lysate
Predicted band size: 33 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com